Montaldo P G, Lanciotti M, Casalaro A, Cornaglia-Ferraris P, Ponzoni M
Pediatric Oncology Research Laboratory, G. Gaslini Children's Hospital, Genoa, Italy.
Cancer Res. 1991 Aug 15;51(16):4342-6.
The modalities of uptake and storage of iodine-labeled m-iodobenzylguanidine (MIBG) by four human neuroblastoma cell lines have been studied. SK-N-BE(2)C cell line has been shown to possess the specific (type 1) MIBG uptake, as well as an efficient extravesicular storage mechanism. Conversely, LAN-5 cells, which show a nonsaturation kinetic of MIBG incorporation, lack only the ability to efficiently store the MIBG taken up by a mechanism that can be pharmacologically defined as uptake 1. The two other neuroblastoma cell lines tested, GI-LI-N and GI-CA-N, lack both uptake and storage capacity. In view of the fact that the only detailed study on specific MIBG uptake by a human neuroblastoma cell line has been carried out on SK-N-SH, a highly heterogeneous cell line, our report provides new insights on the molecular and cellular pharmacology of radiolabeled MIBG.
对四种人神经母细胞瘤细胞系摄取和储存碘标记的间碘苄胍(MIBG)的方式进行了研究。已证明SK-N-BE(2)C细胞系具有特异性(1型)MIBG摄取以及高效的囊泡外储存机制。相反,表现出MIBG掺入非饱和动力学的LAN-5细胞仅缺乏通过一种可在药理学上定义为摄取1的机制有效储存所摄取MIBG的能力。测试的另外两种神经母细胞瘤细胞系GI-LI-N和GI-CA-N既缺乏摄取能力也缺乏储存能力。鉴于对人神经母细胞瘤细胞系特异性MIBG摄取的唯一详细研究是在高度异质性的SK-N-SH细胞系上进行的,我们的报告为放射性标记MIBG的分子和细胞药理学提供了新的见解。